Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFAZ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,719
Award facts
- Contract value 100% obligated
- $25,718.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,718.76 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pens. This delivery order, issued on January 15, 2026, with an ultimate completion date of January 16, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. The award represents a single delivery against DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that was awarded to the company on November 13, 2025, with a $499,999,999 ceiling value extending through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's global military healthcare supply chain, leveraging its established capabilities to distribute a comprehensive range of specialty pharmaceuticals, biologics, and medical consumables to military medical facilities worldwide. The company's substantial contracting activity with the Defense Logistics Agency Medical Supply Chain division demonstrates consistent performance across diverse therapeutic categories, positioning it to fulfill specialized pharmaceutical requirements for federal military healthcare operations under the PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DR26FFAZ2?
SPE2DR26FFAZ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FFAZ2 worth?
The government has obligated $25,719 on SPE2DR26FFAZ2.
Is contract SPE2DR26FFAZ2 an order under another contract?
Yes. SPE2DR26FFAZ2 is a delivery order under SPE2DR25D9225, an indefinite delivery contract.
Was contract SPE2DR26FFAZ2 competed?
The extent of competition for SPE2DR26FFAZ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award